On the morning of September 28, the commencement ceremony of a major project named Shanghai Unicar-Therapy Intelligent Manufacturing Life Technology Co., Ltd. (Hereinafter referred to as Unicar-Therapy) was held in Luodian Town, Baoshan District. Chen Jie, secretary of Baoshan District Party Committee, Lu Dongsheng, co-chairman of Guosheng Industry Transformation Capital, and Yu Lei, chairman and chief scientist of Unicar-Therapy attended the ceremony.

Chen Jie announced the commencement of this project.

Unicar-Therapy is planned to land in the phase I of Guosheng-invested Baoshan MEDI PARK in North Shanghai Biomedical Industrial Park (Baoshan Industrial Park), which is the first major project launched in the PARK, with a building area of about 10,000 square meters, a total investment of RMB 150 million and an output value of about RMB 500 million.

Unicar-Therapy will build an internationally advanced research, industrialization and commercialization center for gene and cell therapy with a scale of RMB 10 billion, a world-class innovative technology transformation center for immunotherapy tumor, and an advanced and high-end industry chain center for genetically engineered immune cells. The center mainly provides mass production services for CAR-T products and CDMO services for plasmids, viruses and CAR-T cells. Unicar-Therapy will add new impetus to the development of Baoshan Industrial Park in the subdivision of cell and gene therapy with its world-class engineered cell therapy technology assisted by its synthetic biology and artificial intelligence technology as well as its capabilities of innovating the products’ research and development and mass production.

Carrier Delivery Ceremony

Speech by Lu Dongsheng, co-chairman of Guosheng Industry Transformation Capital

Speech by Yu Lei, chairman and chief scientist of Unicar-Therapy

Unicar-Therapy focuses on solving the clinical hard nut of CAR-T. Guided by the "clinical value" and with the help of synthetic biology and artificial intelligence technology, it initiates in-depth independent innovation to create a new generation of unique immune cell therapy products. Since its establishment in 2015, the company has successfully launched a number of innovative CAR-T products based on its multiple ingenious technology platforms. The product pipeline includes autologous, allogeneic and universal cell therapy products for the treatment of hematological tumors, solid tumors and autoimmune diseases. In September 2020, Unicar-Therapy successfully obtained the clinical trial license of ssCART-19 cell injection, the world's first safe CAR-T product. This product can be used for the treatment of central nervous system leukemia, a contraindication of CAR-T, which is a milestone in the treatment of hematological tumors by CAR-T therapy. In July 2022, ssCART-19 cell injection, a product independently developed by Unicar-Therapy, was further granted Orphan Drug Qualification (ODD) by the US Food and Drug Administration (FDA), which helps to further open up the overseas market of this product.

Baoshan Industrial Park is located in Luodian Town, Baoshan District, with a total area of 5.86 square kilometers. It is a "Municipal Biomedical Professional Industrial Park" awarded by Shanghai Municipality in April 2020. In recent years, the Park has successfully attracted a number of high-level projects including Zhaohui Pharma, Bao Pharma, Whittlong Pharma, Chiatai Tianqing Akeso Biopharma, BravoVax, Jingze Biopharma, Medicilon, Orient Gene, Cheerland Biotechnology and Medsun Medical Co., Ltd.. As one of the five characteristic biomedical industrial parks at the municipal level, Baoshan Industrial Park is striving to build a biomedical industrial cluster with global influence. Unicar-Therapy settled in Baoshan, showing the advantages of the Park in industrial atmosphere, innovative elements, enterprise services and park management. In the future, the Park will continue to provide public services with industry characteristics, competitive supporting policies and enterprise ecology for settled enterprises.